Pre-clinical murine models have shown that, in conjunction with activating Teff and CTLs, anti-CTLA-4 mAbs exert anti-tumor activity via antibody-dependent cell-mediated cytotoxicity (ADCC)-mediated depletion of intra-tumoral Tregs [142,143]. The gene discussed is CTLA4; the disease is neoplasm.